|Day Low/High||103.08 / 103.98|
|52 Wk Low/High||83.73 / 114.26|
A study of analyst recommendations at the major brokerages shows that Monsanto Co is the #61 broker analyst pick among those stocks screened by The Online Investor for strong stock buyback activity. To make that list, a stock must have repurchased at least 5% of its outstanding shares over the trailing twelve month period.
A sale or spinoff of this business will likely get the attention of competitors that want to increase their over-the-counter product units.
Monsanto Company (NYSE: MON) announced today that the EPA has approved XtendiMax TM herbicide with VaporGrip TM Technology, a low-volatility dicamba herbicide, for in-crop use with Roundup Ready 2 Xtend ® soybeans and...
Monsanto Company's (NYSE: MON) Pierre Courduroux, senior vice president and chief financial officer, will speak with investors in Boston on Tuesday, November 15 at the Morgan Stanley Global Chemicals and Agriculture...
Stock futures are lower on Tuesday as voters in the U.S. head to the polls to elect the country's next president.
A look at the stock charts for CBS, Constellation Brands, Monsanto and Aetna sheds light on the right time to buy.
A WWF report shows how fragile our hold on the world's ecology is. Does Asia represent the future of food production?
Some of the biggest deals already announced on Wall Street are currently pricing in hefty premiums for investors willing to take the risk.
Monsanto Company (NYSE: MON) announced that its Board of Directors has designated Friday, Jan.
Monsanto Company (NYSE: MON) announced that its Board of Directors has designated Tuesday, December 13, 2016 as the date for a special meeting of shareowners to vote upon the proposal to adopt the merger agreement with...
Strong drug sales allow the German group to increase its full-year earnings forecast, while wilting crop science revenue pose more questions about the wisdom of buying Monsanto.
U.K. lender Lloyds falls after a third-quarter profit miss, while luxury goods maker Kering surges.
Index funds are great, Jim Cramer says, but he encourages investors to do some smart stock picking.
Bayer-Monsanto stands a better chance than AT&T-Time Warner.
This is new doctrine having to do with innovation and the stifling of innovation to create new products.
The Swiss fertilizers maker says regulators in the EU and elsewhere have demanded more information.
M&A dollar volume is down as dealmakers worry about political uncertainties at home and abroad.
Regulatory issues will weigh on this deal, because of populist politics.
Forward-looking purchasing managers' indices and earnings from beleaguered lender Deutsche Bank feature among the other release highlights.
Jim Cramer ponders why M&A is just the start of the story and also wonders what a Democratic sweep would do to the markets.
For starters, trouble for banks, drugs, energy and M&A.
Here is why CBS, Constellation Brands, Monsanto and Aetna will be winners in 2017.
York Capital Management founder Jamie Dinan explained how investors should play the Monsanto (MON), Bayer (BAYRY) deal.
The middle market in M&A may seem like opportunity knocking for bulge bracket bankers, except someone's building a wall.
Bankers with the most deal volume in the third quarter varied across sectors, from regional banks to energy.
In highlights from this week's trading diary and posts, Kass tells us about how the outlook for the market is worsening and shares some pointers on low-priced stocks.